Ardena Expands Nanomedicines Facility with GMP Approval

• Ardena, a Contract Development and Manufacturing Organisation (CDMO), has received Good Manufacturing Practice (GMP) approval for its new analytical laboratories in its expanded nanomedicines facility.

• The €20 million expansion represents a significant investment for Ardena, aiming to advance nanomedicine research and development.

• The new facility has achieved operational status for process development and GMP analytical work, with the GMP license for the new production facility scheduled to be obtained in the coming months.

Ardena, a Contract Development and Manufacturing Organisation (CDMO), has announced the receipt of Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories. This approval is part of the company’s recent expansion of its nanomedicines facility.

The expanded facility includes GMP-compliant cleanrooms to support Ardena’s growing nanomedicines business. It also houses laboratories for process development and analytical work, GMP production space, and warehouse facilities. The new 2,200m2 space, strategically located next to Ardena’s existing 4,000 m2 facilities at Pivot Park, Oss, increases the company’s total footprint at the site by more than 50%.

Harry Christiaens, CEO of Ardena, commented on the expansion: “There is a growing demand for expert nanomedicine services. The €20 million expansion of our advanced nanomedicines facility represents a significant investment for Ardena and underscores our commitment to innovation and excellence in pharmaceutical development.”

Christiaens further added that the expanded capacity will enable Ardena to advance nanomedicine research and development, accelerate the development and manufacturing of groundbreaking nanomedicine drugs, and bring novel therapies from concept to clinic in a timely and efficient manner.

Following a successful inspection by the Dutch Healthcare Authority, the facility has achieved operational status for process development and GMP analytical work. The GMP license for the new production facility is expected to be obtained in the coming months, enabling full operational capabilities. These developments align seamlessly with Ardena’s mission of expertly guiding clients through every stage of drug development with expertise and precision.